Infant Bacterial Therapeutics AB (IBT B)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014143)
◆英語タイトル:Infant Bacterial Therapeutics AB (IBT B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014143
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:31
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Infant Bacterial Therapeutics AB (IBT), a subsidiary of BioGaia AB is a pharmaceutical company that develops prophylactic therapies for the medical needs of the premature infant. The company develops pharmaceutical drug candidates for gastrointestinal neonatal condition that causes mucosal injury, necrosis, perforation in the intestinal tracts of infants and death. It offers its products for treating necrotizing enterocolitis, a medical condition primarily seen in premature infants, where portions of the bowel undergo necrosis. IBT’s IBP-9414 drug candidate, containing a co-evolved human bacterial strain derived from human breast milk, is used for the prevention of NEC in premature infants. The company’s IBP-1016 drug candidate is used for the treatment of an unmet medical need in gastroschisis. It operates through a network of neonatologists and research groups. IBT is headquartered in Stockholm, Sweden.

Infant Bacterial Therapeutics AB (IBT B) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Infant Bacterial Therapeutics Enters into Licensing Agreement with BioGaia 10
Equity Offering 11
Infant Bacterial Therapeutics Raises USD12 Million in Rights Offering of Shares 11
BioGaia to Invest USD4.1 Million in Infant Bacterial Therapeutics 12
BioGaia Raises Additional USD0.52 Million from Infant Bacterial Therapeutics 13
Infant Bacterial Therapeutics AB – Key Competitors 14
Infant Bacterial Therapeutics AB – Key Employees 15
Infant Bacterial Therapeutics AB – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Financial Announcements 17
Aug 28, 2017: Infant Bacterial Therapeutics: Interim Management Statement, January 1 – June 30, 2017 17
May 04, 2017: Infant Bacterial Therapeutics: Interim Management Statement, January 1 – March 31, 2017 20
Feb 14, 2017: Infant Bacterial Therapeutics Interim report January 1 – December 31 2016 21
Aug 19, 2016: Infant Bacteria Therapeutics Reports Interim Results for January 1- June 30 2016 22
Corporate Communications 24
Oct 12, 2016: Infant Bacterial Therapeutics appoints new CFO 24
Product Approvals 25
Mar 31, 2016: IBT receives Rare Pediatric Disease Designation from FDA for drug candidate 25
Jan 08, 2016: BioGaia’s subsidiary IBT has US IND open and Swedish CTA approved for clinical study 26
Clinical Trials 27
Sep 11, 2017: Infant Bacterial Therapeutics announces that top line data demonstrate similar safety and tolerability profile in the active and placebo groups 27
Jan 24, 2017: Last patient enrolled in IBT’s Phase 2 study 28
Nov 21, 2016: Positive recommendation from the independent Data Safety Monitoring Board to continue Phase II Study 29
Jun 07, 2016: Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Infant Bacterial Therapeutics AB, Deals By Therapy Area, 2011 to YTD 2017 8
Infant Bacterial Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Infant Bacterial Therapeutics Enters into Licensing Agreement with BioGaia 10
Infant Bacterial Therapeutics Raises USD12 Million in Rights Offering of Shares 11
BioGaia to Invest USD4.1 Million in Infant Bacterial Therapeutics 12
BioGaia Raises Additional USD0.52 Million from Infant Bacterial Therapeutics 13
Infant Bacterial Therapeutics AB, Key Competitors 14
Infant Bacterial Therapeutics AB, Key Employees 15

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Infant Bacterial Therapeutics AB (IBT B)-製薬・医療分野:企業M&A・提携分析(Infant Bacterial Therapeutics AB (IBT B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆